Recomendaciones para la atención odontológica frente a la pandemia por COVID-19 / SARS CoV-2 - Facultad de Odontología - Universidad de Chile

www.odontologia.uchile.cl 36. Gurgel BCV, Borges SB, Borges REA, Calderón PDS. COVID-19: Perspectives for the management of dental care and education. J Appl Oral Sci. 2020 Sep 28;28: e20200358. 37. Islam MS, Rahman KM, Sun Y, Qureshi MO, Abdi I, Chughtai AA, Seale H. Current knowledge of COVID-19 and infection prevention and control strategies in healthcare settings: A global analysis. Infect Control Hosp Epidemiol. 2020 Oct;41(10):1196-1206. 38 .https://www.ada.org/en/member-center/member-benefits/practice-resources/dental-insurance/dental-benefits-to-dental-insurance 39. Howard BE. High-Risk Aerosol-Generating Procedures in COVID-19: Respiratory Protective Equipment Considerations. Otolaryngol Head Neck Surg. 2020 Jul;163(1):98-103 40. Vergara-Buenaventura A, Castro-Ruiz C. Use of mouthwashes against COVID-19 in dentistry. Br J Oral Maxillofac Surg. 2020 Oct;58(8):924-927. 41. Papi P, Di Murro B, Penna D, Pompa G. Digital prosthetic workflow during COVID-19 pandemic to limit infection risk in dental practice. Oral Dis. 2021 Apr;27 Suppl 3:723-726 42. Review: Recommendations, Practices and Infrastructural Model for the Dental Radiology Set-up in Clinical and Academic Institutions in the COVID-19 Era”, Anu Sushanth. A y cols., Biology 2020, 9, 33 43. Dental radiographic procedures during COVID‑19 outbreak and normalization period: recommendations on infection control”, Betul Ilhan y cols., Oral Radiology (2020) 36:395–399 44. EggersM, Koburger-Janssen T, Ward LS, Newby C, Muller S (2018) Bactericidal and virucidal activity of povidone-iodine and chlorhexidine gluconate cleansers in an in vivo hand hygiene clin- ical simulation study. Infect Dis Ther 7(2):235–247. https://doi.org/ 10.1007/s40121- 018-0202-5 45.- Popkin DL, Zilka S, Dimaano M, Fujioka H, Rackley C, Salata R, Griffith A, Mukherjee PK, GhannoumMA, Esper F (2017) Cetylpyridinium chloride (CPC) exhibits potent, rapid activity against influenza viruses in vitro and in vivo. Pathog Immun 2(2): 252–269. 46. www.supersalud.gob.cl/observatorio/671/articles-19667_sem_2_4.pdf 47. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, Villamizar-Peña R, Holguin-Rivera Y, Escalera-Antezana JP, et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis. 2020 34:101623.